Related Experiment Video
Updated: Jun 16, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Rational targeting in acute promyelocytic leukemia
1Aristotle University of Thessaloniki, School of Medicine, Laboratory of Biological Chemistry, University Campus PO Box 1686, Thessaloniki 54124, Greece. papanikn@med.auth.gr
In Vivo (Athens, Greece)
|February 6, 2010
Summary
This study proposes a novel approach for acute promyelocytic leukemia (APL) treatment. Combining low-dose all-trans retinoic acid with kinase inhibitors may improve efficacy and reduce toxicity compared to current therapies.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute promyelocytic leukemia (APL) is characterized by the PML-RARalpha fusion oncogene.
- PML-RARalpha drives APL pathogenesis and is targeted by all-trans retinoic acid (ATRA).
- Current ATRA and chemotherapy treatments for APL are toxic and lead to relapse.
Purpose of the Study:
- To propose a novel therapeutic strategy for APL.
- To investigate the potential of combining low-dose ATRA with small molecule kinase inhibitors.
Main Methods:
- Theoretical proposal based on molecular mechanisms of APL.
- Focus on targeting PML-RARalpha and cyclin-dependent kinases.
Main Results:
- The proposed combination therapy may induce granulocytic differentiation and remission.
- This approach is hypothesized to be as or more efficacious than current treatments.
- Reduced toxicity and lower relapse rates are anticipated.
Conclusions:
- Targeting APL with low-dose ATRA and kinase inhibitors offers a promising alternative.
- This strategy may overcome the limitations of current high-dose therapies.
- Further research is warranted to validate this novel therapeutic approach.
